Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Nature Communications

Volumn 6, Issue , 2015, Pages

  Küçük, Can ^a   Jiang, Bei ^a   Hu, Xiaozhou ^a   Zhang, Wenyan ^b   Chan, John K C ^c   Xiao, Wenming ^d   Lack, Nathan ^e   Alkan, Can ^f   Williams, John C ^a   Avery, Kendra N ^a   Kavak, Painar ^g   Scuto, Anna ^a   Sen, Emel ^e   Gaulard, Philippe ^h   Staudt, Lou ⁱ   Iqbal, Javeed ^j   Zhang, Weiwei ^j   Cornish, Adam ^j   Gong, Qiang ^k   Yang, Qunpei ^b   Sun, Hong ^b   D'Amore, Francesco ^l   Leppä, Sirpa ^m   Liu, Weiping ^b   Fu, Kai ^b   De Leval, Laurence ⁿ   McKeithan, Timothy ^a   Chan, Wing C ^a   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e KOÇ UNIVERSITY   (Turkey)

^f BILKENT UNIVERSITY   (Turkey)

^g BOGAZICI UNIVERSITY   (Turkey)

^h UNIVERSITÉ PARIS EST CRÉTEIL   (France)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; MUTANT PROTEIN; PHOSPHOTYROSINE; STAT5B PROTEIN; IL2 PROTEIN, HUMAN; INTERLEUKIN 2; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; LYMPHOCYTE ANTIGEN RECEPTOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

DISEASE TREATMENT; INHIBITION; MOLECULAR ANALYSIS; MUTATION; PARTHENOGENESIS; PROTEIN; TUMOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER GROWTH; CONTROLLED STUDY; GAMMA DELTA T LYMPHOCYTE; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MEASUREMENT; MOLECULAR MODEL; MUTATOR GENE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; PROTEIN PHOSPHORYLATION; STAT3 GENE; STAT5B GENE; SURFACE PLASMON RESONANCE; T CELL LYMPHOMA; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; T LYMPHOCYTE SUBPOPULATION;

BINDING SITES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTIDINE; HUMANS; INTERLEUKIN-2; JANUS KINASE 1; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MUTATION; PHOSPHOTYROSINE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS;

EID: 84923076524     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7025     Document Type: Article

References (44)

1. Jaffe, E. S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am. Soc. Hematol. Educ. Program 2009, 523-531 (2009).
2. Kwong, Y. L. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19, 2186-2194 (2005).
3. Takakuwa, T. et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 21, 4702-4705 (2002).
4. Quintanilla-Martinez, L. et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am. J. Pathol. 159, 2095-2105 (2001).
5. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
6. Koo, G. C. et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2, 591-597 (2012).
7. Bouchekioua, A. et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28, 338-348 (2013).
8. Kimura, H. et al. Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leuk. Lymphoma 55, 962-963 (2014).
9. Iqbal, J. et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 25, 348-358 (2011).
10. Delabie, J. et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 118, 148-155 (2011).
11. Chan, J. K. et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am. J. Surg. Pathol. 35, 1557-1569 (2011).
12. Kanai, T. et al. Identification of STAT5A and STAT5B target genes in human T cells. PLoS ONE 9, e86790 (2014).
13. Silva, M. et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274, 22165-22169 (1999).
14. Li, G. et al. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 115, 1416-1424 (2010).
15. Kopp, K. L. et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 12, 1939-1947 (2013).
16. Fatrai, S., Wierenga, A. T., Daenen, S. M., Vellenga, E. & Schuringa, J. J. Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood 117, 3320-3330 (2011).
17. Nagy, Z. S. et al. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol. Cancer 8, 67 (2009).
18. Johnston, J. A., Bacon, C. M., Riedy, M. C. & O'Shea, J. J. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J. Leukoc. Biol. 60, 441-452 (1996).
19. Johnston, J. A. et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 .Proc. Natl Acad. Sci. USA 92, 8705-8709 (1995).
20. Derenzini, E. et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 1, e46 (2011).
21. Pardanani, A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22, 23-30 (2008).
22. Sonbol, M. B. et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther. Adv. Hematol. 4, 15-35 (2013).
23. Ohgami, R. S., Ma, L., Monabati, A., Zehnder, J. L. & Arber, D. A. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica 99, e105-e107 (2014).
24. Odejide, O. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293-1296 (2014).
25. Ohgami, R. S. et al. STAT3 mutations are frequent in CD30 T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 27, 2244-2247 (2013).
26. Jerez, A. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120, 3048-3057 (2012).
27. Koskela, H. L. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. New Engl. J. Med. 366, 1905-1913 (2012).
28. Rajala, H. L. et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121, 4541-4550 (2013).
29. Kiel, M. J. et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124, 1460-1472 (2014).
30. Iqbal, J. et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23, 1139-1151 (2009).
31. Nagata, H. et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 97, 708-713 (2001).
32. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
33. Abecasis, G. R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
34. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
35. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
36. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
37. Kucuk, C. et al. HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. Am. J. Pathol. 182, 49-55 (2013).
38. Somanchi, S. S., Senyukov, V. V., Denman, C. J. & Lee, D. A. Expansion, purification, and functional assessment of human peripheral blood NK cells. J. Vis. Exp. e2540 (2011).
39. Kucuk, C. et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc. Natl Acad. Sci. USA 108, 20119-20124 (2011).
40. Piva, R. et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J. Clin. Oncol. 28, 1583-1590 (2010).
41. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
42. Comeau, S. R., Gatchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20, 45-50 (2004).
43. Thomsen, R. & Christensen, M. H. MolDock: a new technique for highaccuracy molecular docking. J. Med. Chem. 49, 3315-3321 (2006).
44. Donaldson, J. M. et al. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Proc. Natl Acad. Sci. USA 110, 17456-17461 (2013).